Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | SVP, Chief Scientific Officer | March 15, 2013 | March 19, 2013 |
| CHIMERIX INCCMRX · Entity 80651 | Director | June 28, 2017 | June 29, 2017 |
| IQVIA HOLDINGS INC.IQV · Entity 3058 | Director | April 23, 2026 | April 27, 2026 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director · President and CEO | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date March 15, 2013 · Filed March 19, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.01 par valueSEC Table I · non-derivative | Direct | 107,320 |
Ending reported balance
After 2013-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2013-03-15 · Exercise / conversion · Acquired 46,700 · Balance 154,020 Row 2 · 2013-03-15 · Sale · Disposed 46,700 · Balance 107,320 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.86 · Expires 2018-02-14 | Direct | 46,700 |
Reported balance
After 2013-03-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2013-03-15 · Exercise / conversion · Disposed 46,700 · Balance 46,700 |
| Common stock, $0.01 par valueSEC Table I · non-derivative | IndirectProfit sharing trust | 6,473 |
Reported balance
Holding disclosure · report date 2013-03-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,473 F1: Balance in the AbbVie Savings Program as of March 15, 2013. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the AbbVie Savings Program as of March 15, 2013.
CHIMERIX INC
Report date June 28, 2017 · Filed June 29, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2027-06-27 | Direct | 21,000 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 21,000 · Balance 21,000 F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting.
IQVIA HOLDINGS INC.
Report date April 23, 2026 · Filed April 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,946 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Grant · Acquired 1,571 · Balance 16,946 F1: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant.
Intellia Therapeutics, Inc.
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,147,064 |
Ending reported balance
After 2026-08-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-20 · Sale · Disposed 19,890 · Balance 1,149,849 F1: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price. Row 2 · 2026-08-21 · Sale · Disposed 2,785 · Balance 1,147,064 F1: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 58,415 |
Reported balance
Holding disclosure · report date 2026-08-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 58,415 F3: Shares held by the John M. Leonard 2015 Irrevocable Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price.
F3: Shares held by the John M. Leonard 2015 Irrevocable Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vitae Pharmaceuticals, Inc
Report date October 25, 2016 · Filed October 25, 2016
Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.85 · Expires 2025-07-28 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-10-25 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2: This option, which provided for vesting in equal quarterly installments over three years following July 29, 2015, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
F2: This option, which provided for vesting in equal quarterly installments over three years following July 29, 2015, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
F3: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 3,123 | $157.75 | $492,653.25 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 8 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,844 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.395 to $158.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 4,758 | $156.96 | $746,815.68 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 7 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,967 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.31 to $157.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 15,567 | $155.70 | $2,423,781.90 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 6 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,725 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.31 to $156.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 7,428 | $154.98 | $1,151,191.44 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 5 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,292 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.31 to $155.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,334 | $153.66 | $358,642.44 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 4 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,720 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.22 to $154.13, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,055 | $152.81 | $314,024.55 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,054 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.21 to $153.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 27,167 | $14.58 | $396,094.86 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 11,637 | $13.40 | $155,935.80 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 27,139 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0001209191-21-053305 · doc4.xml · derivative · entry 6 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,138 Underlying: Common Stock · 27,139 shares Expires 2030-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 23, 2021. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 100 | $153.52 | $15,352.00 |
DisclosureSEC source: 0001209191-21-053305 · doc4.xml · nonDerivative · entry 4 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,305 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 8,165 | $153.08 | $1,249,898.20 |
DisclosureSEC source: 0001209191-21-053305 · doc4.xml · nonDerivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,405 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.38 to $153.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 18,874 | $151.54 | $2,860,165.96 |
DisclosureSEC source: 0001209191-21-053305 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,570 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.38 to $152.18, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 27,139 | $13.40 | $363,662.60 |
DisclosureSEC source: 0001209191-21-053305 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 22,682 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0001209191-21-052835 · doc4.xml · derivative · entry 6 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,277 Underlying: Common Stock · 22,682 shares Expires 2030-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 19, 2021. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,963 | $152.30 | $908,164.90 |
DisclosureSEC source: 0001209191-21-052835 · doc4.xml · nonDerivative · entry 4 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,305 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.055 to $152.80, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 6,993 | $151.56 | $1,059,859.08 |
DisclosureSEC source: 0001209191-21-052835 · doc4.xml · nonDerivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,268 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.02 to $152.015, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 9,726 | $150.46 | $1,463,373.96 |
DisclosureSEC source: 0001209191-21-052835 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,261 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.96, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 22,682 | $13.40 | $303,938.80 |
DisclosureSEC source: 0001209191-21-052835 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 21:04 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | GrantCommon Stock | 934 | $0.00 | $0.00 |
DisclosureSEC source: 0001478242-21-000036 · wf-form4_161886622846061.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,678 F1 · shares: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:50 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 15,937 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-21-026891 · doc4.xml · derivative · entry 5 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,937 Underlying: Common Stock · 15,937 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on January 6, 2021. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:50 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-21-026891 · doc4.xml · derivative · entry 4 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:50 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 15,937 | $13.88 | $221,205.56 |
DisclosureSEC source: 0001209191-21-026891 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:50 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-21-026891 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 00:46 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 26,041 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0001209191-21-024889 · doc4.xml · derivative · entry 7 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,959 Underlying: Common Stock · 26,041 shares Expires 2030-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested as to 106,250 shares as of April 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 00:46 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-21-024889 · doc4.xml · derivative · entry 6 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 45,000 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 135,000 shares as of April 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 00:46 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 13,895 | $83.00 | $1,153,285.00 |
DisclosureSEC source: 0001209191-21-024889 · doc4.xml · nonDerivative · entry 4 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 693,368 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 00:46 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 26,041 | $13.40 | $348,949.40 |
DisclosureSEC source: 0001209191-21-024889 · doc4.xml · nonDerivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 00:46 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 24,314 | $84.00 | $2,042,376.00 |
DisclosureSEC source: 0001209191-21-024889 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681,222 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 00:46 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 45,000 | $14.58 | $656,100.00 |
DisclosureSEC source: 0001209191-21-024889 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:50 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantRestricted Stock Unit · Derivative | 31,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018323 · doc4.xml · derivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,394 Underlying: Common Stock · 31,394 shares Expires not disclosed F2 · derivative.exercise_price: On March 3, 2021, the reporting person was granted 31,394 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · date: On March 3, 2021, the reporting person was granted 31,394 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 31,394 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 31,394 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:50 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 188,363 | $0.00 Strike: $57.71 | $0.00 |
DisclosureSEC source: 0001209191-21-018323 · doc4.xml · derivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,363 Underlying: Common Stock · 188,363 shares Expires 2031-03-02 F1 · derivative.exercise_date: This option was granted on March 3, 2021 with respect to 188,363 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 01:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 56,718 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-21-009083 · doc4.xml · derivative · entry 9 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,516 Underlying: Common Stock · 56,718 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 9, 2021. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 01:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 28,043 | $75.00 | $2,103,225.00 |
DisclosureSEC source: 0001209191-21-009083 · doc4.xml · nonDerivative · entry 6 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,536 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 01:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 56,718 | $6.83 | $387,383.94 |
DisclosureSEC source: 0001209191-21-009083 · doc4.xml · nonDerivative · entry 5 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 01:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0001209191-21-009083 · doc4.xml · derivative · entry 8 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,453 Underlying: Common Stock · 40,000 shares Expires 2030-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 92,082 shares as of February 5, 2021. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 01:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 881 | $68.78 | $60,595.18 |
DisclosureSEC source: 0001209191-21-009083 · doc4.xml · nonDerivative · entry 4 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 631,861 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.53 to $69.03, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 5, 2021 at each separate price. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 01:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 14,018 | $67.86 | $951,261.48 |
DisclosureSEC source: 0001209191-21-009083 · doc4.xml · nonDerivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,742 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.52 to $68.345, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 5, 2021 at each separate price. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 01:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 8,043 | $67.18 | $540,328.74 |
DisclosureSEC source: 0001209191-21-009083 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,760 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.495, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 5, 2021 at each separate price. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 01:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 40,000 | $13.40 | $536,000.00 |
DisclosureSEC source: 0001209191-21-009083 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 67,060 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · derivative · entry 27 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,940 Underlying: Common Stock · 67,060 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F19 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 95,000 shares as of February 1, 2021. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $22.78 | $0.00 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · derivative · entry 26 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 165,000 shares as of February 1, 2021. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 36,858 | $73.00 | $2,690,634.00 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · nonDerivative · entry 20 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614,803 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 67,060 | $13.88 | $930,792.80 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · nonDerivative · entry 19 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 30,998 | $72.00 | $2,231,856.00 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · nonDerivative · entry 18 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,601 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 50,000 | $22.78 | $1,139,000.00 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · nonDerivative · entry 17 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $22.78 | $0.00 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · derivative · entry 25 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 60,000 shares Expires 2028-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 165,000 shares as of February 1, 2021. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · derivative · entry 24 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 30,000 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 55,885 shares as of February 1, 2021. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · derivative · entry 23 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on January 6, 2021. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · derivative · entry 22 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,234 Underlying: Common Stock · 100,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 02:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,475 | $65.04 | $356,094.00 |
DisclosureSEC source: 0001209191-21-007638 · doc4.xml · nonDerivative · entry 16 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,599 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.76 to $65.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.